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Abstract
Purpose To examine the value of urinary 5-hydroxy-N-
methyl-2-pyrrolidone (5-HNMP) and 2-hydroxy-N-meth-
ylsuccinimide (2-HMSI) in a population of workers
exposed to N-methyl-2-pyrrolidone (NMP) and to look for
health effects of exposure to this organic solvent.
Methods Airborne NMP was determined according to the
NIOSH method. Urinary 5-HNMP and 2-HMSI (after and
before next shift) were determined by liquid chromatog-
raphy with tandem mass spectrometry. Outcomes were
effects on lung, kidney, skin and mucous membranes,
nervous system, haematopoiesis and liver determined by
clinical examination and laboratory measurements. Uni-
variate statistical methods and multiple regressions were
used to analyse results. Skin resorption, smoking and other
potential confounders were taken into account.
Results Three hundred twenty-seven workers were eligi-
ble out of which 207 workers (63 %) participated. Ninety-
one of these worked with NMP. Occupational exposure to
NMP did often not occur daily and ranged from non-
detectable to 25.8 mg/m3 (median = 0.18). Urinary
2-HMSI (mg/l; before next shift) was the best biomarker of
exposure to NMP, explaining about 70 % of the variance,
but most likelihood ratios did not allow for ruling exposure
in or out, at these low levels of exposure. Creatinine
adjustment did not improve the results clearly. No clear
and consistent health effects could be associated with NMP
exposure. No indication for a bias due to non-participation
was found.
Conclusions Biological monitoring, primarily urinary
2-HMSI (mg/l; before next shift), is of value to estimate
exposure to NMP even when exposure is irregular and low.
Likelihood ratios of urinary 5-HMNP or 2-HMSI are,
however, not quite satisfactory at these low levels. No
irritant or other health effects were found.
Keywords Biological monitoring 
N-methyl-2-pyrrolidone  Skin uptake  Irritation
Introduction
N-methyl-2-pyrrolidone (NMP; CAS 872-50-4) is a solvent
used in the petrochemical industry, as a reaction medium in
the polymer industry and as a stripping and cleaning agent
in the electronics industry. It is a formulating agent in inks,
dyes and pesticides and is a constituent of paint stripper
and products for graffiti removal.
Two main sources give information about NMP toxic-
ity in humans. The first one is made of experimental
exposures typically conducted in small groups of young,
healthy volunteers, who neither smoked nor consumed
alcohol. At the most, these studies support a very limited
irritant effect at airborne concentrations up to 160 mg/m3
(Vanthriel et al. 2007; Akesson and Paulsson 1997) or
after dermal application of 300 mg NMP (undiluted or
diluted) for 6 h in Finn chambers (Akesson et al. 2004).
By contrast, workplace studies, which represent the
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second main source of information, have suggested toxic
skin reactions (Jungbauer et al. 2001; Leira et al. 1992)
and irritant effects (Langworth et al. 2001) even at levels
as low as 3 mg/m3 (Beaulieu and Schmerber 1991).
Nephrotoxicity has been suggested at low concentrations
too (geometric mean of 8-h time-weighted average con-
centrations in breathing zone air of 0.66, range
0.03–4.52 mg/m3) (Langworth et al. 2001). A limitation of
this second source is that it is comprised mainly of case
series. Therefore, a sound risk assessment is difficult (Poet
et al. 2010) as exemplified by the 8-h limit values in
Europe (20–200 mg/m3) (Gestis Database, accessed
December 2012). Other effects on nervous system, hae-
matopoiesis and liver have been suggested, but the liter-
ature is scarce (Carnerup 2004).
Some divergences between the conclusions of the
studies (particularly irritant effects) may be explained by
higher peak and/or mixed exposures, significant dermal
absorption of liquid and/or vapour NMP (Bader et al. 2008;
Akesson et al. 2004) and workplace micro-environment
(temperature and humidity) (Carnerup et al. 2006). How-
ever, careful scrutiny of the available literature (Vanthriel
et al. 2007) and power calculations strongly suggest that
methodological factors (power, exposure assessment, co-
exposures, definition of outcomes and statistical analyses)
are probably an important source of variation as well. A
further issue is the correlation between exposure to NMP
and urinary metabolites as biological monitoring may be
less useful under field conditions than assumed on the basis
of the volunteer studies (Bader et al. 2007; Jonsson and
Akesson 2003; Akrill et al. 2002). Indeed, volunteer studies
were carried out under well-standardised and well-con-
trolled conditions, which did not reflect everyday working
conditions (Anundi et al. 2000). Therefore, it had also to be
checked whether correlation coefficients of 0.8–0.9, which
were found in volunteer studies, could also be found under
field conditions.
It has been suggested that cytochrome P450 2E1
(CYP2E1) activity (phenotype) should be taken into
account for an accurate interpretation of biological moni-
toring of exposure to NMP on the basis of an experiment in
12 human volunteers (Ligocka et al. 2003), but the influ-
ence of CYP2E1 genetic polymorphism on the interpreta-
tion of biological monitoring of NMP exposure is still
unknown.
To assess reliably (correlation and likelihood ratio) the
value of biomarkers of exposure under field conditions and
the possible local and systemic effects of exposure to NMP
(lung, kidney, skin and mucous membranes, nervous sys-
tem, haematopoiesis and liver), a cross-sectional study with
suitable power and taking into account dermal absorption,
micro-environment (temperature and humidity) and
CYP2E1 genotypes was conducted.
Methods
The cross-sectional study was carried out between 2006
and 2011 in northeast Switzerland. As there is no list of
plants using NMP, companies were identified with several
methods (Internet searches, contact with NMP vendors or
occupational health specialists or other sources of infor-
mation) and asked for participation (Fig. 1). Controls were
comparable subjects from the same or another plant.
Regarding power, assuming that irritation is an critical
effect of NMP and that an exposure to about 1–3 mg/m3
(0.25–0.75 ppm) is sufficient to increase the prevalence of
respiratory symptoms 2–4 times (Langworth et al. 2001;
Anundi et al. 2000; Beaulieu and Schmerber 1991), it is
necessary to examine two groups with 60 subjects each to
disclose a threefold increase in prevalence (10 and 30 % in
the non-exposed and exposed group, respectively) with a
probability of 80 % and at a significance level of 5 %.
With respect to kidney effects (Langworth et al. 2001), a
study population of at least 75 non-exposed and 75 exposed
subjects are necessary to reach a power of about 85–90 %,
given the following assumptions: urinary albumin in non-
exposed subjects (geometric mean ± standard deviation)
5.3 ± 1.8 mg/g, significance level of 5 %, postulated true
difference between groups of 0.9 mg/g.
Exposure was either due to graffiti removal or through
other uses of NMP. The graffiti removers used several
61 plants asked for participation
9 no answer or refusals
21 plants included (10 with their own control 
subjects) 
One plant lost (no order for tasks with NMP any 
longer); one control plant became redundant 
(power requirements met)
29 not eligible (28: NMP use too low; 1 plant too 
small and far away)
Fig. 1 Selection procedure and reasons for non-inclusion
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NMP-containing products applying these with a cloth or a
brush. An aerosol could arise when hot water was sprayed
to complete the graffiti removal. The time necessary to
remove the graffiti was very variable according to colour
and surface, ambient temperature, etc. The other compa-
nies or firms used NMP as a solvent, in the production
(cleaning agents, coatings, polymers, etc.) or in syntheses.
Exposure to NMP did not always occur daily but depended
on the orders the company had.
All persons gave their informed consent prior to inclu-
sion into the study. The participants underwent a semi-
structured clinical examination. The coding of the answers
was reviewed by the study coordinator and divergences
resolved by checking information and codes. Questions
about respiratory symptoms and conditions were taken
from the SAPALDIA study without changing the wording
(Zemp et al. 1999; Leuenberger et al. 1998; Ackermann-
Liebrich et al. 1997). Smoking was assessed with questions
from the questionnaire of the European Community of
Steel and Coal, revision 1967. Thirteen of the 16 questions
were transposed from the Q16 questionnaire into German.
The Q16 questionnaire was developed to monitor early
effects of neurotoxic exposures in working populations
(Lundberg et al. 1997). Two questions (‘‘Do you some-
times feel an oppression of your chest’’ and ‘‘Do you often
have a painful tingling in some part of your body’’) were
already queried in other questions of the checklist and
were, therefore, not included as well as the question ‘‘Do
you have any problems with buttoning and unbuttoning’’.
Current symptoms were defined as having occurred during
the 4 weeks prior to the clinical examination if not defined
otherwise (for example questions from the SAPALDIA
study). Work-related symptoms were defined as those
brought about by a specific task, occurring during a specific
task in coworkers as well and without other cause.
With respect to metabolite concentration, ‘‘exposed to
NMP’’ means current average monthly duration of expo-
sure to NMP [ 0 h. With respect to health effects, expo-
sure was defined by a lifelong exposure score (Hotz et al.
1989) with additional questions about NMP use. The par-
ticipants were categorised into five subgroups according to
the results of the occupational exposure score: never
exposed to NMP or organic solvents, formerly exposed
only, current exposure to NMP only, current exposure to
organic solvents but not to NMP and current exposure to
NMP and organic solvents.
Suitable masks were defined as personal protective
equipment suitable for removing NMP (based on an eval-
uation of the constituents of the mask according to a walk-
through of the workplace), worn for at least 50 % of the
working time and maintained correctly (according to
occupational history). Suitable gloves were defined as
made from butyl or latex and worn for at least 50 % of the
working time. Both questions on masks and gloves were
related to usual conditions. Furthermore, wearing gloves
and contact with products (wet skin, splashes on skin and
hand washing with organic solvents) on the day of the
biomonitoring and NMP concentration (per cent) in the
products mostly used on the day of the biomonitoring
(middle of the percentage range) were also recorded.
Spirometry was carried out according to the ATS criteria
(American Thoracic Society 1995) and results assessed
independently by two physicians. Predicted values of
forced expiratory volume in the 1st second (FEV1 per cent
predicted) were calculated according to Quanjer et al.
(1993). Non-Caucasians were excluded from these
calculations.
Workplace temperature and humidity were measured at
the beginning and at the end of the shift, and the mean was
calculated.
5-hydroxy-NMP (5-HNMP) and 2-hydroxy-N-methyl-
succinimide (2-HMSI) were selected because they repre-
sent a large fraction of NMP metabolites found in urine and
have a fairly long half-life (about 6 and 26 h, respectively)
(Bader et al. 2008), which is more suitable with irregular
exposure patterns, and since there is no risk of external
contamination (Bader et al. 2007; Akesson et al. 2004;
Akesson and Jonsson 1997). Both parameters were mea-
sured in urine at the end of the shift (ES) on the day of air
sampling and before the next shift, i.e. after about 16 h off
work and before any exposure due to the next shift (BNS)
(Akrill et al. 2002). As clinical examination may decrease
exposure, air sampling was carried out on a different day
(within ± 1 week of the clinical examination).
5-HNMP and 5-HNMP-d4 were synthesised by Syn-
thelec (Lund, Sweden), 2-HMSI was purchased from
Sigma Aldrich, and 2-HMSI-d3 was synthesised by Ram-
idus AB (Lund, Sweden).
The samples were analysed in the laboratory of the
Louvain centre for Toxicology and Applied Pharmacology
(Universite´ catholique de Louvain, Belgium) without
knowledge of their exact provenance (blind analysis).
Airborne NMP was collected by personal sampling over
a whole workday with solid sorbent tubes (Coconut shell
charcoal, 100/50 mg; SKC 226-01) and pumps
(150 ml/min) (SKC model 210-2002, SKC, Inc., Eighty-
Four, PA) which were calibrated before and after personal
sampling. NMP was determined according to the NIOSH
method (NIOSH 1994). Limit of quantification (LOQ) was
0.3 lg. Among the 66 blanks, 63 (95 %) did not contain
any NMP. In the three remaining tubes, 1.8, 0.5 and 0.4 lg
were found.
5-HNMP and 2-HMSI were quantified in urine samples
using a method previously described (Suzuki et al. 2009)
with slight modifications. Briefly, urine samples were only
diluted 10 times with an aqueous solution containing
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deuterated compounds (5-HNMP-d4 and 2-HMSI-d3) as
internal standards, and chromatographic separation was
performed on a Zorbax Eclipse Plus C18 analytical col-
umn, 100 mm long 9 4.6 mm i.d., 3.5 lm particle size
(Agilent). The mobile phase consisted of a gradient of
0.1 % formic acid in aqueous solution and acetonitrile. The
liquid chromatography with tandem mass spectrometry
(LC–MS/MS) system used was a 6460 Triple Quad LC/MS
from Agilent.
Using this LC–MS/MS validated method, the LOQ was
set as 0.2 mg/l for both NMP metabolites (5-HNMP and
2-HMSI) and the laboratory has obtained successful results
(including a certificate for successful participation) in
external quality assessment scheme organised by the
Institute for Occupational, Environmental and Social
Medicine of the University of Erlangen, Germany, during
the period of samples analysis (G-EQUAS 49).
A concentration equal to half the LOQ was attributed to
samples below this limit.
Methods for determining serum Clara cell protein
(CC16), urinary albumin (U-alb) and retinol-binding pro-
tein (U-RBP) have been described elsewhere (Steiner et al.
2005; Bernard and Lauwerys 1983). Serum creatinine
(S-creatinine) and gamma-glutamyltransferase (GGT)
activity were determined with an Olympus AU2700 ana-
lyser (Olympus, Hamburg, Germany). Blood cells were
counted automatically. After liquid–liquid extraction of
alkalinised urine (NaOH 8 N), cotinine concentration was
measured with high performance liquid chromatography-
diode array detection. Limit of quantification was 0.05 mg/l
and variation coefficient \10 % for values higher than
0.2 mg/l. Samples below the limit of quantification were
attributed a concentration equal to half that limit.
CYP2E1 genotypes were determined in a limited sub-
population (n = 93). Genomic DNA was extracted from
whole blood using QIAamp DNA Mini Kit (Qiagen), and
CYP2E1 genotyping was performed using methods previ-
ously described for CYP2E1*1B (A1/A2), CYP2E1*5
(c1/c2) and CYP2E1*6 (D/C) (Haufroid et al. 1998) and
CYP2E1*1D (insertion) (Nomiyama et al. 2001),
respectively.
Statistical analysis
Statistical analysis was performed using SAS 9.2 statistical
software (SAS Institute, Cary, North Carolina, USA).
Variable distributions were examined for normality, and
non-parametric tests or logarithmic transformation used
when appropriate. The efficacy of this logarithmic trans-
formation was reconfirmed by examining the residuals of
the linear regression models before and after transforma-
tion. Subjects with a missing value for one variable were
excluded from the analysis using this variable. Results
under the LOD (or LOQ) were included in the calculations
and were not considered as missing. To exclude a bias due
to these values, regression models including metabolite
concentrations were applied both in exposed workers only
and in the whole group. Indeed, as presented in the
‘‘Results‘‘ section, metabolites concentrations below the
LOQ were found especially in non-exposed workers.
In the multiple linear regression models, the concen-
trations of the NMP metabolites in the urine were adjusted
for urine dilution in two ways: via dividing the metabolite
concentration by urine creatinine concentration and via
including the urine creatinine concentration as a separate
covariate in the regression model. Linear regression models
were laid out before the beginning of the analysis and
included the following covariates as a priori variables: age
(years), smoking (pack years), ex-smoker (number of years
since smoking cessation), GGT (IU/l), S-creatinine (mg/dl)
and creatinine in urine (g/l). Urinary creatinine was not
included in the model for those metabolites which were
previously creatinine adjusted. Additional covariates con-
sidered for inclusion were NMP concentration in the air on
the day of the biomonitoring (mg/m3), current average
monthly duration of exposure to NMP according to occu-
pational history (hours), NMP concentration in the pro-
ducts mostly used on the day of the biomonitoring (per
cent, middle of the range), suitable gloves usually worn at
least 50 % of the time (yes/no), currently having a skin
disease according to clinical history (no/yes), healthy hand
skin (objectively ascertained at clinical examination) (yes/
no), splashes of NMP solution onto the skin on the day of
the biomonitoring (no/yes), gloves worn on the day of the
biomonitoring (yes/no), did hands stay dry on the day of
the biomonitoring (yes/no) and genetic factors (see above).
Dichotomous variables had the code 0 for the most
favourable situation (for example, no splashes) or the
healthy state. To decide on which variables to retain in the
final model, the Bayesian information criterion (BIC),
Akaike’s information criterion (AIC) and the explanatory
value (adjusted r2) were used. Variables were included in
the final model if they substantially lowered the BIC and
the AIC and increased the adjusted r2 value, were statisti-
cally significant or were based on a priori knowledge. If the
information gained by BIC, AIC and adjusted r2 value did
not indicate the same, all three were considered carefully
and the BIC was given more weight than the AIC and
adjusted r2 value. Multiple linear regression models were
built for only the exposed group as well as the whole
sample. Each of the models was evaluated for the
assumptions of linear regression and also assessed for
collinearity by examination of variance inflation factors.
The screening accuracy of a biomarker is determined
among other by the accuracy with which it can rule in or
rule out exposure, which can be quantified by the
666 Int Arch Occup Environ Health (2014) 87:663–674
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likelihood ratios (LRs). Therefore, LRs were calculated to
characterise the screening accuracy of 5-HNMP and
2-HMSI for excluding or identifying exposure to NMP
(defined as no hour of exposure to NMP compared to one
or more hours of exposure to NMP). Thus, 5-HNMP and
2-HMSI concentrations were subdivided into 3 categories
defined as low, medium and high and corresponding to
\80, 80–120 and [120 % of the maximum metabolite
concentration in the unexposed group. LRs[10 or\0.1 are
considered to provide strong evidence for a biomarker
being suitable for identifying or excluding exposure (Deeks
and Altman 2004).
Results
Three hundred twenty-seven workers were eligible to
participate out of which 207 (63 %) participated; 113
declined participation and 7 could not be examined due to
organisational reasons. In these 327 subjects, neither age
(p = 0.9) nor nationality (p = 0.5) (statistical analysis
limited to the 230 subjects from 5 countries with [10
representatives) differed between participants and non-
participants. Seven of the 8 eligible women declined par-
ticipation, and hence, the only woman remaining was
excluded leaving 206 male workers for statistical analysis.
Firms differed widely with respect to participation
(5–100 %), but no statistically significant difference in
airborne NMP was found between plants on the basis of a
participation cutoff of 20 % (p = 0.2; Wilcoxon two-
sample test).
Information on demographics and main exposure char-
acteristics are presented in Table 1. In the participants, the
number of nationalities was very similar to that in all eli-
gible subjects. Indeed, more than 14 nationalities were
represented, but only 3 of them had more than 10 repre-
sentatives (n = 18, 18 and 94 from Germany, Italy and
Switzerland, respectively), limiting statistical analyses with
this variable. Median (5th–95th percentile) lifetime dura-
tion of occupational exposure to NMP was 0 (0–0), 3.6
(1.7–6.10) and 2.05 (0.1–15.0) years in the subjects never
occupationally exposed to NMP and/or organic solvents,
currently occupationally exposed to NMP only, and cur-
rently exposed to NMP and other organic solvents. In the
formerly exposed workers (n = 22), median time elapsed
since cessation of exposure was 12.5 years (5th–95th
percentile: 2.2–34.4). Only one worker had a previous
exposure to NMP and other solvents, but no one had a
former exposure to NMP only. The concentration of NMP
in the preparations used by the workers was mainly between
20 and 25 % (n = 28) or 80 and 99 % (n = 36). In the
NMP-exposed group and on the day of the biological mon-
itoring, hands were seldom washed with solvent(s) (n = 3).
Median (5th and 95th percentile) duration of airborne
sampling was 450 (310–525) min. Airborne NMP and uri-
nary metabolite concentrations are presented in Table 2.
Airborne NMP concentrations hardly correlated with
workplace humidity and temperature (Spearman q = -0.12
and -0.01, respectively, p [ 0.09). Many subjects did not
work every day with NMP. Indeed, on the day of the clinical
examination, only 37 (43 %) workers reported having
worked with NMP on the previous day.
Table 1 Characteristics of the study population
Unexposed
workers
(n = 114)
Exposed
workers
(n = 91)
Age (years) 44 (23–59) 45 (22–60)
Education level
Low 26 (23) 36 (40)
Middle 80 (70) 53 (58)
High 8 (7) 2 (2)
Smoking
Never smoker 38 (34) 24 (26)
Ex-smoker 25 (22) 17 (19)
Current smoker 50 (44) 50 (55)
Pack years (in smokers only) 15.9 (1.4–65.8) 18.9 (1.0–54.0)
Alcohol
No/only socially 95 (83) 67 (74)
Daily 19 (17) 24 (26)
BMI (kg/m2)
18.5 to \25.0 31 (27) 34 (37)
25.0 to \30.0 57 (50) 39 (43)
C30 26 (23) 18 (20)
S-creatinine (mg/dl) 0.90 (0.72–1.15) 0.89 (0.66–1.14)
GGT (IU/L) 24 (12–57) 26 (12–67)
Current average monthly
duration of exposure to NMP
(h)
0 (0–0) 10 (1–100)
Use suitable mask ([50 % of
the time)
13 (15)
Use suitable gloves ([50 % of
the time)
30 (33)
Any gloves today (yes) 62 (71)
Suitable gloves today (yes) 25 (29)
No wet hands today 50 (58)
NMP splash on the skin today
(yes)
22 (29)
‘‘Exposed to NMP’’ means current average monthly duration of
exposure to NMP [ 0 h. One worker with a missing value is excluded
from the table
Figures are median (5th–95th percentile) or number (per cent). In this
table, ‘‘today’’ refers to the day of the biomonitoring in NMP-exposed
subjects only
Reference range for S-creatinine and GGT are 0.6–1.4 mg/dl and
7–50 IU/l, respectively
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Urinary metabolites (mg/l) and creatinine concentrations
were not significantly correlated (p [ 0.4). Urinary
metabolites correlated with airborne NMP concentrations
(0.6 \ Spearman q\ 0.8) with the highest correlation
between airborne NMP and 2-HMSI concentration (mg/l)
in the BNS sample (Spearman q = 0.83; p \ 0.0001;
n = 193). Correlations between age and metabolite con-
centrations were of borderline statistical significance. No
statistically significant correlation was found between
BMI, smoking (pack years, daily cigarettes and urinary
cotinine) and metabolite concentration (p [ 0.6 and 0.3,
respectively). The number of workers with metabolite
concentrations below the LOQ depended on exposure and
metabolite. Concentrations below the LOQ occurred less
often in exposed than non-exposed workers, and 2-HMSI
was less often under the LOQ than 5-HNMP. 2-HMSI (ES
sample) was non-detected in 3/87 exposed workers only,
which represents the lowest percentage (3.4 %) of con-
centrations below the LOQ found in the study. In contrast,
5-HNMP (BNS sample) was under the LOQ in 89/106 non-
exposed workers (84 %).
The main results of the multiple linear regressions for
the exposed group are summarised in Table 3. As the
2-HMSI concentration (mg/l; BNS) showed the highest
correlation with the NMP concentration in the air and as
the results were relatively constant across the different
metabolites, the multiple linear regression models for this
biomarker will be illustrated. For the exposed workers,
after adjusting for age, pack years, time since cessation of
smoking, GGT, S-creatinine and urinary creatinine, the
addition of the concentration of NMP in the air caused the
biggest change in the BIC, AIC and adjusted r2 value
(adjusted r2 = 0.62 compared to adjusted r2 = 0.1 without
air concentration). After addition of duration of exposure to
NMP and further addition of the concentration of the NMP
solution into the model, another increase in the adjusted r2
value to 0.67 and 0.71, respectively, was achieved. Fur-
thermore, having a skin disease increased the explanatory
value of the model to 0.73. Wearing a mask had no sta-
tistically significant effect. The final multiple linear
regression models for all the other biomarkers had sub-
stantially lower adjusted r2 values, but were consistent with
the finding that the air concentration was the most essential
covariate. Using the sum of 5-HNMP and 2-HMSI did not
improve the association with airborne NMP (Figs. 2, 3, 4,
5).
In the whole group, the main results were quite con-
sistent with those found in the exposed group only
(Table 4). However, the distribution of residuals was
clearly less satisfactory than in the exposed group.
Including all workers, after adjusting for age, pack years,
time since smoking cessation, GGT, S-creatinine and cre-
atinine in urine, similar to the exposed group adding the
NMP concentration caused the biggest change in the BIC,
the AIC and the adjusted r2 value (adjusted r2 = 0.035
compared to 0.715 after taking the air NMP concentration
into account). After addition of the duration of exposure to
NMP and further including having a skin disease into the
model, the adjusted r2 value increased to 0.746 and 0.750,
respectively. Similar to the analysis of the exposed group,
the final linear regression models of the other NMP
metabolites gave considerably lower adjusted r2 values.
Based on the relationship between ambient NMP and
urinary 5-HNMP ES or 2-HMSI BNS and assuming line-
arity, biological indices corresponding to an airborne NMP
concentration of 80 mg/m3 could be approximated crudely
by extrapolation. The tentative value obtained for 5-HNMP
ES of 91 mg/l is similar to the one of 100 mg/l proposed by
the American Conference of Industrial Hygienists. With
respect to 2-HMSI (BNS), the tentative value would be
Table 2 Airborne NMP and urinary metabolites
Non-exposed
workers (n = 114)
Exposed workers
(n = 91)
Airborne NMP
(mg/m3)a
0.01 (0.002–0.40) 0.18 (0.002–6.99)b
Airborne NMP not
detectable (n; %)
38 (34) 8 (9)
Urinary metabolites (mg/l)
End of shift
5-HNMP 0.10 (0.10–0.80) 0.60 (0.10–29.00)
2-HMSI 0.30 (0.10–1.50) 0.80 (0.20–23.30)
Before shift
5-HNMP 0.10 (0.10–0.60) 0.45 (0.10–22.90)
2-HMSI 0.30 (0.10–2.40) 1.55 (0.10–58.00)
Urinary metabolites (mg/g creatinine)
End of shift
5-HNMP 0.09 (0.04–0.60) 0.39 (0.05–41.41)
2-HMSI 0.23 (0.07–1.04) 0.56 (0.11–19.89)
Before shift
5-HNMP 0.06 (0.04–0.32) 0.27 (0.04–10.51)
2-HMSI 0.20 (0.06–1.39) 1.06 (0.09–42.89)
Humidity (%) 50.2 (25.9–66.9) 51.0 (30.5–72.0)
Temperature (C) 20.7 (10.2–26.4) 20.3 (1.0–24.3)
‘‘Exposed to NMP’’ means current average monthly duration of
exposure to NMP [ 0 h
Figures are median and 5th–95th percentile
There were 3–8 missing values according to the measurement
considered
Concentrations in exposed and non-exposed workers always differ at
p \ 0.0001 (Wilcoxon two-sample test)
a A concentration equal to half the limit of quantification was
attributed to samples below this limit (see ‘‘Methods’’ section)
b 0.89, 2.77 and 25.83 mg/m3 for the 75th and 90th percentile and
the maximum, respectively
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about 257 mg/l. This value should be considered as ten-
tative only because it is an evident approximation caused
by a threefold extrapolation of the airborne concentration
data.
With respect to LRs, in the category ‘‘low’’, the lowest
LR was obtained for creatinine-adjusted 2-HMSI in the
second urine sample and was well above 0.1 (0.293, 95 %
CI 0.259–0.331), suggesting that 5-HNMP and 2-HMSI are
not suitable for ruling out exposure. For the category
‘‘high’’, LR amounted to 4–8. The best result was obtained
for the creatinine-adjusted 5-HNMP in the second urine
sample (9.86, 95 % CI 6.30–15.44). In other words, if the
prevalence (pre-test probability) of exposure is 50 %, a LR
of 10 means that the post-test probability of being exposed
amounts to 90 % when the 5-HNMP concentration (cre-
atinine-adjusted 5-HNMP in the second urine) is in the
high category, suggesting that this urinary metabolite is a
fair (but not very good) biomarker for ruling in exposure.
In the genotyped subpopulation (n = 93), no influence
of genetic factors was found on the NMP metabolite con-
centrations and the number of workers carrying
CYP2E1*1D (insertion), the allele assumed to be the most
important one (http://www.cypalleles.ki.se/cyp2e1.htm),
was too small for meaningful statistical analyses (n = 7).
Respiratory and neuropsychological symptoms were
compared among the 5 subgroups presented in Table 5 on
the basis of 28 clinical questions (eye, nose or throat irri-
tation, cough, phlegm, wheeze, memory, concentration,
Table 3 2-HMSI and 5-HNMP (log transformed, in mg/l, before next shift) in the exposed group: multiple linear regression models
Model 1 Model 2 Model 3
2-HMSIa P 2-HMSIa p 5-HNMPa p
Sample size 66 66 66
Intercept -0.06147 0.9 0.06224 0.9 -0.14582 0.9
Age (years) 0.00221 0.7 0.00142 0.8 0.00863 0.2
Pack years (number) -0.00071 0.9 -0.00024 0.9 0.00243 0.6
Time since smoking cessation (years) 0.00167 0.8 0.00296 0.7 0.00600 0.5
GGT (IU/L) 0.00201 0.5 0.00123 0.7 0.00100 0.8
S-creatinine (mg/dl) -0.09306 0.8 -0.25110 0.5 -0.91202 0.04
Urine creatinine (g/l) -0.03296 0.7 -0.02942 0.7 0.13740 0.2
NMP concentration in aira (mg/m3) 0.56255 \0.0001 0.54045 \0.0001 0.63890 \0.0001
Exposure to NMP (h)b 0.00686 0.0002 0.00696 0.0004 0.00412 0.08
NMP concentration in solutiona, c (%) 0.32231 0.02 0.38285 0.01 0.24652 0.2
History of any current
skin disease (no/yes)d
0.39766 0.03 0.31719 0.09 NI
Healthy hand skin (yes/no)e NI NI 0.28696 0.08
Gloves worn (yes/no)f NI -0.17750 0.2 -0.79036 0.003
Suitable gloves ([50 % of the time) (yes/no)g NI NI 0.82543 0.002
Splashes of NMP solution on skinf (no/yes) NI 0.21346 0.1 NI
Adjusted r2 0.73 0.74 0.62
Pr [ F \0.0001 \0.0001 \0.0001
Figures indicate the partial regression coefficient with the corresponding significance level. Model 1 was found to have the lowest Bayesian
Information Criterion; therefore, the variables identified in model 1 were also included in multiple linear regression models for the other
metabolites. The following adjusted r2 values were obtained: 2-HMSI in the first urine sample (uncorrected for creatinine)—0.5742, 2-HMSI in
the first urine sample (corrected for creatinine)—0.6432, 2-HMSI in the second urine sample (corrected for creatinine)—0.6523, 5-HNMP in the
in first urine sample (uncorrected for creatinine)—0.3805, 5-HNMP in the second urine sample (uncorrected for creatinine)—0.5528, 5-HNMP in
the first urine sample (corrected for creatinine)—0.4110, 5-HNMP in the second urine sample (corrected for creatinine)—0.5189
NI variable not included in this run
a Log transformed
b Current average monthly duration of exposure to NMP according to occupational history (hours)
c NMP concentration in the products mostly used on the day of the biomonitoring (middle of the range)
d Question from clinical history
e Objectively ascertained at clinical examination
f On the day on the biomonitoring
g Suitable gloves usually worn at least 50 % of the time
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headache, dizziness, depressed without reason, fatigue,
etc.). The number of symptomatic (work-related or not)
cases was mostly low (below 10 or even 5 in each cell)
making interpretation quite difficult and consideration of
possible confounders impossible. However, a closer
examination of the results for each variable to detect pos-
sible patterns did not disclose consistent and clear trends
towards more symptoms in a specific subgroup. Alike, no
clinically significant difference appeared regarding skin
disease (history and status) or pallesthesia. Table 5 pre-
sents selected laboratory measures in these subgroups. No
statistically significant effect of NMP exposure was
observed for haematological variables either (haemoglobin,
haematocrit, erythrocytes, leucocytes, granulocytes, lym-
phocytes, thrombocytes, details not shown). Grouping
together all subjects non-exposed to NMP and comparing
them to those exposed to this organic solvent did not alter
these conclusions. Despite higher power, the significance
level (Kruskal–Wallis test) of the difference in urinary
albumin increased to 0.20 after excluding three obvious
outliers (67 \ albumin \ 343 mg/g) diagnosed with a
20-year diabetes or hypertension (systolic and diastolic
pressure [150 and [104 mmHg) suggesting no occupa-
tional association either. In the subgroup of never smokers,
symptoms of cough, phlegm or wheeze as well as FEV1
(per cent predicted) were not associated with exposure to
NMP.
Overall, exposure to organic solvents was low. Indeed,
by comparing the prevalence of acute solvent-induced
work-related symptoms (Hotz et al. 1992) in all workers
exposed to any organic solvents to that of all non-exposed
subjects, only feeling drunk was related to work (13
exposed subjects, p = 0.02).
Discussion
This large study conducted in northeast Switzerland
included 21 firms representing a large spectrum of activi-
ties and 91 workers exposed to NMP. The purpose was to
examine the value of urinary 5-HNMP and 2-HMSI for
assessing an occupational exposure to NMP and to look for
health effects. A group of workers exposed only to organic
solvents but not to NMP was included to increase the
ability to detect possible differences, if any, in outcomes
between NMP and other solvents.
Urinary metabolites correlated very well with airborne
NMP concentrations, although these concentrations were
Fig. 2 Plot of the association between airborne NMP (mg/m3) and
concentration of 5-HNMP (BNS; mg/l) in 86 exposed workers
(logarithmic transformation). A = 1, B = 2 observations, etc.).
r = 0.76, p B 0.0001
Fig. 3 Plot of the association between airborne NMP (mg/m3) and
concentration of 2-HMSI (BNS; mg/l) in 86 exposed workers
(logarithmic transformation). A = 1, B = 2 observations, etc.).
r = 0.85, p B 0.0001.
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low. Indeed, r2 reached values of about 60–70 %. The
association was not confounded by age, BMI or smoking.
However, at least at these exposure levels, a limitation was
that the urinary metabolites had too high LRs to rule out
exposure. By contrast, 5-HNMP (creatinine-adjusted, BNS)
could be used to rule in exposure to this organic solvent.
Interestingly, using the sum of 5-HNMP and 2-HMSI did
not improve the association with airborne NMP, although
the half-lives of these metabolites differ.
There were NMP metabolites in non-exposed subjects.
Interestingly, in the control group (n = 10) examined by
Anundi et al. (2000), mean 5-HNMP (range) was
0.37 mmol/mol creatinine (0.02–2.96), which agrees very
well with the mean 5-HNMP (range) of 0.31 (0.03–7.6)
found in the present study. Regarding 2-HMSI, the corre-
sponding concentrations were 0.16 mmol/mol creatinine
(0.04–0.56) and 0.36 (0.04–5.95), respectively. The
occurrence of NMP metabolites in both control groups
strongly suggests that there is some exposure of the control
subjects. This exposure may be either occupational (con-
tamination of the rooms the control subjects are working
in) or non-occupational (household products such as cloth
cleaning or stripping agents). In this population, skin
resorption played a minor role. However, as the hands were
not immersed constantly in NMP, changing gloves fre-
quently may offer enough protection even if gloves are not
quite impermeable.
Surprisingly, the creatinine adjustment did not work
well, although only spot urine samples were collected. In
this regard, findings are contradictory. Akesson et al.
(2004) and Akesson and Jonsson (2000) reported that
adjustment for creatinine or density did not always work,
whereas according to Akrill et al. (2002) adjusting by
creatinine concentration represents an improvement.
According to Jonsson and Akesson (2003), creatinine
adjustment should work better for 5-HNMP and 2-HMSI
than for NMP and methylsuccinimide because of their
higher renal clearance compared to that of creatinine.
Actually, this was not confirmed in the present study.
On the day of the measurements, the upper range of
airborne NMP concentrations included concentrations
above the concentration of 0.4 mg/m3 that was recom-
mended to protect from irritant effects (Beaulieu and
Schmerber 1991). Thus, some irritant effects could have
been expected. Even if a lack of irritant effects due to too
few subjects exposed to toxicologically significant con-
centrations cannot be excluded, a more consistent expla-
nation is a genuine lack of effect. Indeed, well-controlled
studies have not confirmed the irritant effect, and the
Fig. 4 Plot of the association between airborne NMP (mg/m3) and
concentration of 5-HNMP (ES; mg/l) in 87 exposed workers
(logarithmic transformation). A = 1, B = 2 observations, etc.).
r = 0.74, p B 0.0001
Fig. 5 Plot of the association between airborne NMP (mg/m3) and
concentration of 2-HMSI (ES; mg/l) in 87 exposed workers (loga-
rithmic transformation). A = 1, B = 2 observations, etc.). r = 0.69,
p B 0.0001
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Table 4 2-HMSI and 5-HNMP (log transformed, mg/l) in the whole group: multiple linear regression models
Model 1 Model 2 Model 3
2-HMSI (BNS) p 5-HNMP (BNS) p 5-HNMP (ES) p
Sample size 183 183 182
Intercept 0.53431 0.03 0.1486 0.6 0.53878 0.07
Age (years) 0.00399 0.2 0.00514 0.1 -0.00283 0.4
Pack years (number) 0.00031 0.9 -0.00067 0.7 0.00124 0.6
Time since smoking cessation (years) -0.00051 0.9 0.00121 0.8 -0.00572 0.2
GGT (IU/L) 0.00028 0.9 0.00354 0.05 0.00116 0.6
S-creatinine (mg/dl) -0.36334 0.09 -0.56055 0.02 -0.29202 0.2
Urine creatinine (g/l) 0.08971 0.04 0.00782 0.9 0.01426 0.8
Airborne NMP concentration (mg/m3) 0.51423 \0.0001 0.42273 \0.0001 0.50339 \0.0001
Exposure to NMP (h)a 0.00558 \0.0001 0.00670 \0.0001 0.00163 0.3
History of any current skin disease (no/yes)b 0.16437 0.06 NI NI
Adjusted r2 0.75 0.66 0.59
Pr [ F \0.0001 \0.0001 \0.0001
Figures indicate the partial regression coefficient with the corresponding significance level. The variables identified in model 1 were also
included in multiple linear regression models for the other metabolites. The following adjusted r2 values were obtained: 2-HMSI in the first urine
sample (uncorrected for creatinine)—0.5791, 2-HMSI in the first urine sample (corrected for creatinine)—0.585, 2-HMSI in the second urine
sample (corrected for creatinine)—0.7223, 5-HNMP in the first urine sample (uncorrected for creatinine)—0.5950, 5-HNMP in the second urine
sample (uncorrected for creatinine)—0.6570, 5-HNMP in the first urine sample (corrected for creatinine)—0.5444, 5-HNMP in the second urine
sample (corrected for creatinine)—0.6063
NI variable not included in this run, ES end of the shift on the day of air sampling, BNS before the next shift, i.e. after about 16 h off work and
before any exposure due to the next shift
a Current average monthly duration of exposure to NMP according to occupational history (hours)
b Question from clinical history
Table 5 Selected outcomes in the different exposure subgroups
Never exposed
(n = 30)
Former exposure to
solvents (n = 22)
Current exposure to
NMP only (n = 8)
Current exposure to
solvents (no NMP)
(n = 98)
Current exposure
(solvents and NMP)
(n = 38)
p value
2-HMSIa (mg/l; BNS) 0.30 (0.10–1.60) 0.40 (0.10–10.70) 1.75 (1.10–50.20) 0.40 (0.10–8.80) 2.90 (0.10–239.0) \0.0001
5-HNMPa (mg/g; BNS) 0.06 (0.04–0.19) 0.06 (0.04–0.83) 2.57 (0.05–8.67) 0.08 (0.04–1.79) 0.65 (0.06–89.55) \0.0001
Lifetime occupational
exposure to NMP
(years)
0 (0–0) 0 (0–0) 3.60 (6.10–1.70) 0 (0–0) 2.05 (0.10–15.0) \0.0001
GGT (IU/l) 21 (12–72) 25 (10.5–125) 25.5 (15–43) 23 (12–68) 27.5 (14–67) 0.3
Serum creatinine (mg/dl) 0.89 (0.73–1.16) 0.89 (0.76–1.12) 0.95 (0.70–1.04) 0.89 (0.66–1.15) 0.94 (0.58–1.32) 0.7
Urinary albuminb (mg/g) 2.72 (0.48–10.21) 3.92 (0.46–13.04) 0.54 (0.40–67.74) 3.62 (0.32–27.52) 4.65 (0.73–225.32) 0.06
Urinary RBPb (lg/g) 27.91 (0.62–107.81) 28.57 (0.73–276.81) 16.22 (2.28–318.42) 45.56 (0.79–133.78) 42.79 (1.08–163.89) 0.8
Serum CC16 (lg/l)c 15.40 (6.90–30.50) 13.95 (7.80–27.40) 12.10 (9.0–20.60) 14.00 (8.00–23.10) 15.70 (4.00–27.70) 0.3
FEV1 (per cent
predicted)d
99.69 (70.23–108.52) 94.69 (65.02–119.35) 96.12 (54.50–119.85) 97.69 (75.28–118.26) 94.21 (74.97–112.32) 0.5
Definition of subgroups according to lifetime exposure to NMP and organic solvents (see ‘‘Methods’’ section)
Figures are median and 5th and 95th percentile. n subgroup size, p level of significance of the differences between different exposure subgroups (Kruskal–Wallis)
HMSI (mg/l; BNS) and HNMP (mg/g; BNS) had the highest r2 and LR, respectively (see text)
a A concentration equal to half the limit of detection was attributed to samples below the limit of detection (see ‘‘Methods’’ section)
b 13 missing values. There were 5 and 25 concentrations \LOD for urinary albumin and RBP, respectively. The distribution of RBP concentrations \LOD did not
differ significantly between groups
c 32 missing values
d Caucasian participants only (n = 186)
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findings reported by Beaulieu and Schmerber (1991) are
likely to be biased (Vanthriel et al. 2007). Moreover, the
irritant effect described by Langworth et al. (2001) was
likely due to esters rather than to NMP. As many workers
did not work daily with NMP, habituation reducing the
irritant effects is an unlikely explanation too.
Clear clues to neurological, renal, haematological or
hepatic effects could not be found, which is in line with the
scarce data from the literature (Carnerup 2004).
With respect to CYP2E1 genotypes, no effect appeared
in the subpopulation examined. Determinations of the
phenotype may give other results, as suggested by Ligocka
et al. (2003), but this was not planned in this study because
of financial constraints.
A limitation of the study is its cross-sectional design as a
healthy worker effect could not be taken into account. No
information was available on workers having previously
left the plant.
In conclusion, biological monitoring, primarily urinary
2-HMSI (mg/l; BNS), is of value to estimate exposure to
NMP even when exposure is irregular and low. However,
5-HMNP or 2-HMSI cannot be used to rule out such a low-
level exposure to NMP. At the low levels found in this
study, no irritant, renal, haematological or neurological
effects could be found.
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